Julian Adams, PhD

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.

Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale for a phase II trial looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.